Viking Therapeutics, Inc. (VKTX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-07-29) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-04-29) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-11) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-10-22) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-07-23) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-04-23) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-05) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-10-23) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-07-24) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-04-24) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-07) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-10-25) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Agreements With Ligand Pharmaceuticals Incorporated | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Fair Value of Financial Instruments | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Investments In Marketable Securities | ||
| Operating Leases | ||
| Operating Leases - Rou Assets and Lease Liability Obligations | — |
|
| Organization and Summary of Significant Accounting Policies | — |
|
| Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies | — |
|
| Pay Vs Performance Disclosure | ||
| Related Party Transactions | — |
|
| Segment Reporting | ||
| Stock-based Compensation | ||
| Stockholders' Equity | ||
| Subsequent Events | ||
| Warrants | ||